ArriVent BioPharma Inc
AVBPBuild a strategy around AVBP
ArriVent BioPharma Inc AI Insights
Informational only. Not investment advice.Snapshot
- Zero revenue pre-commercial biotech burning 146M TTM FCF with 113M cash - under 12 months runway at current burn rate[Free Cash Flow TTM]
- R&D spend of 141M TTM is 3x industry median (45M), signaling aggressive clinical development pipeline[Research and Development TTM]
- Near-zero debt (0.02% D/E) with 305M equity - clean balance sheet but dilution-dependent funding model[Debt to Equity]
Watch Triggers
- Cash and Equivalents: Falls below 75M or burn accelerates >40M/quarter — Signals imminent dilutive raise; watch for S-3 filings
- Research and Development TTM: Drops >20% without revenue progress — May indicate pipeline setback or strategic pivot
- Net Common Stock Issuance: Exceeds 100M in next 12 months — Dilution above 25% materially impairs per-share value
Bull Case
Trading at 3.1x book with 305M tangible equity and zero debt - downside protected by cash/equity if pipeline fails gracefully
R&D intensity (141M) at 3x industry median suggests advanced-stage clinical assets; success could justify 3-5x current EV
Bear Case
Sub-12 month cash runway (113M cash vs 146M burn) guarantees dilutive financing; 86M raised TTM already diluted 20%+
Zero revenue with 932M market cap is pure option value - clinical failure means 80%+ downside to tangible book
Bull vs Bear Balance
AI-generated sentiment analysis based on fundamental metrics and market conditions.
Leverage AVBP's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.
Forward Thesis
Equity raise of 50-100M likely within 6-12 months to extend runway beyond 2026
- Cash of 113M vs 146M annual burn
- 86M raised via stock issuance TTM
- Zero debt capacity utilized
Binary outcome: clinical success drives 3-5x upside, failure means near-total loss
- Zero revenue, 100% R&D dependent
- EV of 820M implies pipeline value
- No diversification across assets
Valuation Context
Caveats
AVBP Fundamentals
| Metric | Value | YoY Growth | Industry Percentile |
|---|---|---|---|
$1.2B | — | ||
$1.16B | — | ||
0.00 | — | ||
$0 | — | ||
$-4.32 | — | ||
0% | — | ||
0% | — | ||
$-160.59M | — | ||
-58.9% | — | ||
Beta 5Y (Monthly) | unknown | — |
AVBP Dividend History
AVBP Stock Splits
AVBP SEC Filings
| Filing Date | Report Date | Report Type | Filing Link |
|---|---|---|---|
03/05/26 | 12/31/25 | 10-K | |
11/10/25 | 09/30/25 | 10-Q | |
08/11/25 | 06/30/25 | 10-Q | |
05/12/25 | 03/31/25 | 10-Q | |
03/03/25 | 12/31/24 | Unknown | |
11/14/24 | 09/30/24 | 10-Q | |
08/14/24 | 06/30/24 | 10-Q | |
05/08/24 | 03/31/24 | 10-Q | |
03/28/24 | 12/31/23 | 10-K | |
01/26/24 | 09/30/23 | 424B4 | |
10/04/23 | 06/30/23 | DRS/A | |
05/08/24 | 03/31/23 | 10-Q | |
01/26/24 | 12/31/22 | 424B4 | |
09/30/22 | 09/30/22 | Unknown | -- |